What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...
Charles River Laboratories International (NYSE:CRL) reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chi
Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets.
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 1.2% year on y...
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.2% year on ...
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings this Thursday before market hours. Here’s what investors should know. C...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Over the past six months, Charles River Laboratories has been a great trade, beating the S&P 500 by 7.5%. Its stock price has climbed to $168.91, representin...
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Charles River Laboratories (NYSE:CRL) and the rest of the drug development inputs & services stocks fared in Q4.
